Can smarter radiation spare lungs without sacrificing tumor control?
NCT ID NCT06542159
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This phase II trial is testing whether removing the usual safety margin around the tumor during online adaptive stereotactic body radiotherapy (SBRT) can lower breathing-related side effects while still controlling early-stage non-small cell lung cancer or limited lung metastases. About 130 participants will be randomly assigned to receive either standard SBRT with a safety margin or adaptive SBRT without it. The main goal is to see if the adaptive approach reduces severe lung toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy (online adaptive stereotactic body radiotherapy without PTV margin)
What this could lead to
If successful, this approach could reduce breathing-related side effects while still controlling tumors, making radiation safer for patients with early-stage lung cancer or limited lung metastases.
What could go wrong
This is a mid-stage trial with only 130 participants, so results may not apply to everyone. Removing safety margins might increase the risk of missing tumor targets, and long-term outcomes are not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.